Beam Therapeutics Inc. (BEAM)
| Market Cap | 2.92B +105.5% |
| Revenue (ttm) | 139.74M +120.0% |
| Net Income | -79.99M |
| EPS | -0.81 |
| Shares Out | 100.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 466,887 |
| Open | 28.94 |
| Previous Close | 29.17 |
| Day's Range | 28.63 - 29.94 |
| 52-Week Range | 15.35 - 36.44 |
| Beta | 2.19 |
| Analysts | Buy |
| Price Target | 50.75 (+73.86%) |
| Earnings Date | May 6, 2026 |
About BEAM
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylk... [Read more]
Financial Performance
In 2025, Beam Therapeutics's revenue was $139.74 million, an increase of 120.01% compared to the previous year's $63.52 million. Losses were -$79.99 million, -78.77% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for BEAM stock is "Buy." The 12-month stock price target is $50.75, which is an increase of 73.86% from the latest price.
News
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)
Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels
BEAM-302 is Beam's lead genetic disease program for liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that addresses the underlying pathophysiology of both liver and lung disease.
Beam Therapeutics Transcript: Study result
BEAM-302 demonstrated robust efficacy and safety in 29 AATD patients, achieving durable, protective AAT levels and significant reduction of mutant Z-AAT with a single 60 mg dose. The therapy restored physiologic AAT regulation and showed a favorable safety profile, supporting advancement to pivotal trials.
Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development
Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-u...
What's Going On With Beam Therapeutics Stock?
Beam announced a loss per share of 10 cents, far surpassing the consensus estimate of a loss of 99 cents. Additionally, the company reported revenue of $114.11 million, dramatically exceeding expectat...
Beam Therapeutics Earnings Call Transcript: Q4 2025
Expanded liver-targeted pipeline with BEAM-304 for PKU and secured $500M in non-dilutive financing to support risto-cel commercialization and pipeline growth. Strong cash position extends runway into mid-2029, with key clinical milestones ahead.
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026
Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street
$100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Antici...
Beam Therapeutics to Host Investor Webcast for Fourth Quarter and Year-End 2025 Financial Results and New Liver-targeted Genetic Disease Program
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Base editing technology is enabling one-time, durable therapies for genetic diseases, with BEAM-302 and Risto-cel advancing toward regulatory milestones and commercialization. Financial strength and platform scalability support rapid pipeline expansion and strategic partnerships.
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. B iologics Licensing Application (BLA)...
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh...
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
Beam Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Base editing platform advances enable precise gene correction with strong safety and efficacy signals. AATD 302 program targets accelerated approval with robust biomarker data, while the sickle cell program shows rapid engraftment and high efficacy. Cash runway extends into 2028.
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early ...
Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Base editing technology enables precise, repeatable gene correction, with BEAM-101 showing strong clinical results in sickle cell disease and BEAM-302 advancing for alpha-1 antitrypsin deficiency. Cost efficiencies and pipeline expansion are expected, with key data updates in 2025.
Beam Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
The discussion highlighted progress in gene editing for hematology and liver diseases, with BEAM-302 showing strong efficacy and safety in AATD. Early 2026 data will inform optimal dosing and regulatory path, while the sickle cell program advances toward pivotal results and potential approval.
Beam Therapeutics Transcript: Citi's Biopharma Back to School Conference
The company is advancing base editing therapies for hematology and liver diseases, with BEAM-302 showing strong efficacy and safety in AATD and a one-time, durable correction profile. Competitive advantages include higher functional protein levels and a favorable safety profile, with regulatory and commercial milestones expected in early 2026.
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man...
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the...
Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile
Beam Therapeutics Transcript: The European Hematology Association Congress 2025
Updated BEACON trial data show BEAM-101 achieves robust, durable increases in hemoglobin F and resolves anemia in severe sickle cell disease, with no severe VOCs post-engraftment and a favorable safety profile. Manufacturing is efficient and scalable, and market demand is strong.
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to